Docetaxel in combination with metformin enhances antitumour efficacy in metastatic breast carcinoma models: a promising cancer targeting based on PEGylated liposomes.

Abstract

OBJECTIVES:

Metformin has been shown to kill cancer stem-like cells in genetically various types of breast carcinoma. With the aim to simultaneously eradicate the bulk population of tumour cells and the rare population of cancer stem-like cells in breast cancer tissues, we used the combination chemotherapy of docetaxel (DTX) with metformin (MET). Furthermore, we introduce an active loading method based on ammonium sulphate 250 mM (SA) for encapsulating docetaxel into liposomes.

METHODS:

Docetaxel and metformin encapsulated into PEGylated liposomes with two different methods based on remote or passive loading methods, respectively. The size and surface charge of the liposomes were characterized. DTX content in the nanoliposomes was measured by the high-performance liquid chromatography method. The drug release profiles were evaluated in phosphate-buffered dextrose 5% with the pH of 6.5 and 7.4. We examined the antitumour activity of Taxotere (TAX), and liposomal formulation of DTX and MET as a monotherapy or combination therapy. The biodistribution of liposomes was also investigated using 99mTc hexamethyl propylene amine oxime method in BALB/c mice bearing 4T1 breast carcinoma tumours.

KEY FINDINGS:

The final formulations were prepared according to the best physicochemical characteristics which were HSPC/mPEG2000-DSPE/Chol (DTX liposomes) and HSPC/DPPG/mPEG2000-DSPE/Chol (MET liposomes), at molar ratios of 85/5/10 and (55/5/5/35), respectively. In vivo experiments showed that when free or liposomal metformin used in combination with liposomal docetaxel, they prolonged median survival time (MST) from 31 in the control group to 46 days, which demonstrates their promising effects on the survival of the 4T1 breast carcinoma mice models. Moreover, combination therapies could significantly increase life span in comparison with phosphate-buffered saline (PBS) and Taxotere groups at the same dose. Furthermore, in the combination therapy study, treatment with DTX liposomes prepared by ammonium sulphate 250 mM buffer alone resulted in similar therapeutic efficacy to combination therapy. The biodistribution study exhibited significant accumulation of DTX liposomes in the tumours due to the Enhanced Permeability and Retention effect.

CONCLUSIONS:

This study also showed that metformin-based combinatorial chemotherapies have superior efficacy versus their corresponding monotherapy counterparts at same doses. The findings confirm that liposomes based on ammonium sulphate 250 mM could be as a promising formulation for efficient DTX delivering and cancer targeting and therefore merit further investigations.

• Authors: Roghayyeh Vakili-Ghartavol, Amin Mehrabian, Farshad Mirzavi, Seyed Mahdi Rezayat, Mohammad Mashreghi, Leila Farhoudi, Sharmin Kharrazi, Kayvan Sadri, Mahmoud Reza Jaafari
• Journal: The Journal of pharmacy and pharmacology (J Pharm Pharmacol) Vol. 74 Issue 9 Pg. 1307-1319 (Sep 01 2022) ISSN: 2042-7158 [Electronic] England
• PMID: 35833585 (Publication Type: Journal Article)
• Copyright: © The Author(s) 2022. Published by Oxford University Press on behalf of the Royal Pharmaceutical Society. All rights reserved. For permissions, please e-mail: [email protected].

Chemical References

• Antineoplastic Agents
• Liposomes
• Phosphates
• Docetaxel
• Polyethylene Glycols
• Metformin
• Ammonium Sulfate

Topics

• Ammonium Sulfate
• Animals
• Antineoplastic Agents (chemistry)
• Cell Line, Tumor
• Docetaxel (pharmacology)
• Liposomes (chemistry)
• Metformin (pharmacology)
• Mice
• Mice, Inbred BALB C
• Neoplasms
• Phosphates
• Polyethylene Glycols (chemistry)
• Tissue Distribution